Presence of mesenchymal markers (VIM and TWIST1) was higher in metastatic BC patients than in early-stage BC patients [44, 46, 47] and detection of mesenchymal CTCs (CK19−/VIM+) was associated with lymph node involvement [48], suggesting that EMT phenotype is directly related to the metastatic potential of CTCs. Here, TWIST1 is linked to breast cancer.